Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Cantor Fitzgerald raises NVIDIA (NVDA) target; CEO Huang the 'Soothsayer of Santa Clara'
-
NVIDIA (NVDA) PT Raised to $1,200 at Cantor Fitzgerald; Jensen Huang he 'Soothsayer of Santa Clara'
-
Mind Medicine (MNMD) Prices 16.67M Share Offering at $6/sh
-
Cantor Fitzgerald Starts Despegar.com (DESP) at Overweight, 'Valuation Very Attractive'
-
BridgeBio Pharma Inc. (BBIO) Announces Pricing of Public Offering of Common Stock
-
Form 8-K Cantor Fitzgerald Income For: Mar 05
-
BridgeBio Pharma Inc. (BBIO) Announces Proposed $250M Share Offering
-
Akero Therapeutics (AKRO) PT Raised to $61 at Cantor Fitzgerald, 'we would be buyers'
-
PagSeguro (PAGS) PT Raised to $16 at Cantor Fitzgerald
-
Cantor Positive on CIGNA (CI): 'See Upcoming 3/7 Investor Day as Positive Catalyst for CI'
-
Cantor Fitzgerald Maintains BioVie Inc. (BIVI) at Neutral
-
Humacyte (HUMA) Announces Pricing of $40.2 Mln Public Offering of Common Stock
-
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Humacyte (HUMA) Announces Proposed Public Offering of Common Stock
-
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
-
Form NPORT-P CANTOR FITZGERALD INFRAS For: Dec 31
-
Cantor Fitzgerald Starts Teladoc (TDOC) at Overweight, 'trades at a 49% discount to virtual healthcare peers'
-
Janux Therapeutics (JANX) Prices $296.5M Share and Warrant Offering at $46.50/sh
-
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
Regan Capital Launches the Regan Floating Rate MBS ETF (NYSE: MBSF)
-
Janux Therapeutics (JANX) Announces Proposed $175M Share Offering
-
Janux Therapeutics Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Starts Desktop Metal Inc. (DM) at Overweight, 'Expansive Technology Portfolio With Growth Opportunities'
-
Cantor Fitzgerald Starts Markforged Holding Corp. (MKFG) at Overweight, 'Great Technology at a Discounted Price'
-
Cantor Fitzgerald Reiterates Overweight Rating on BigBear.ai Holdings (BBAI)
-
Cantor Fitzgerald Reiterates Overweight Rating on Archer Aviation Inc. (ACHR)
-
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
Intuitive Machines slumps as moon lander likely has 10-20 hours of battery life left
-
StratCap Expands Management Team with Two Key Hires
-
Intuitive Machines shares descend fast after the CEO says the moon lander is on its side
-
Cantor Fitzgerald Starts ORIC Pharamceuticals (ORIC) at Overweight, 'offers attractive risk/reward'
-
Intuitive Machines (LUNR) stock explodes after historic moon landing. Analysts see more room for gains
-
Analyst says Lucid (LCID) stock price may fall 20% as it is 'gasping for air'
-
Cantor Fitzgerald Downgrades Lucid Group Inc. (LCID) to Underweight on 'persistently high negative gross margins, lower-than-expected annual production guidance, and lower demand'
-
NVIDIA (NVDA) PT Raised to $900 at Cantor Fitzgerald, 'remains a TOP PICK'
-
Cantor Fitzgerald Upgrades Root, Inc. (ROOT) to Overweight
-
Cantor Fitzgerald Starts Sabre (SABR) at Overweight (correction)
-
Cantor Fitzgerald Downgrades Rapt Therapeutics (RAPT) to Neutral, 'Too Many Unknowns Right Now'
-
Form N-23C3A/A CANTOR FITZGERALD INFRAS For: Feb 16
-
Form N-23C3A CANTOR FITZGERALD INFRAS For: Feb 16
-
Form 424B3 Cantor Fitzgerald Income
-
Alkermes (ALKS) PT Raised to $43 at Cantor Fitzgerald
-
Newmark Hires Matthew Featherstone as Head of Debt & Structured Finance for the UK and Europe
-
Cantor Fitzgerald Reiterates Overweight Rating on Nano-X Imaging (NNOX) Following NVIDIA Stake
-
Tech-Enabled Private Credit Asset Manager Liquidity Group Strengthens Ties with Institutional Investors with Senior Hires
-
KalVista Pharmaceuticals (KALV) Prices $160.1M Offering at $15.25/sh
-
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
-
Orchid Island Capital Announces February 2024 Monthly Dividend and January 31, 2024 RMBS Portfolio Characteristics
-
KalVista Pharmaceuticals (KALV) Announces Proposed Share and Warrant Offering